Aptevo Therapeutics (APVO) provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the ...
Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a ...
which triggers 4-1BB signaling to stimulate NK cell proliferation and IFN-γ secretion. 4-1BBL is often co-administered with other cytokines to enhance the activation of NK cells. 3. Augment DC antigen ...
Eutilex’s CEO, Byoung S. Kwon, is a leading immuno-oncology researcher responsible for the discovery of the human 4-1BB, an inducible costimu-latory receptor expressed on activated T cells.
The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.
The Phase 1b study is evaluating givastomig, a potential best-in-class, Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, targeting CLDN18.2-expressing tumor cells for the treatment of gastric ...
APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell ...
Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a l ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback